March 29, 2019
Millendo Reports Full Year 2018 Operating and Financial Results
–Initiated ZEPHYR, a pivotal Phase 2b/3 clinical study of livoletide for patients with Prader-Willi syndrome (PWS), in 1Q19– –Topline data…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Millendo Therapeutics
March 19, 2019
Millendo Therapeutics Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome
Top-line Phase 2b results are expected in 1H 2020 and may support an NDA submission for livoletide ANN ARBOR, Mich.–(BUSINESS…